Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Venticute · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| Venticute | DRUG | Patients With Pneumonia or Aspiration of Gastric Contents and Intubation/Ventilation/Oxygenation Impairment |
Main inclusion criteria: * Patient has been intubated due to one of the following primary pulmonary insults: aspiration of gastric contents or pneumonia Main exclusion criteria: * Principal source of infection or sepsis is outside the lung * Severe pre-existing lung disease * Cancer metastatic to...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| AstraZeneca PLC | AZN | 1 | PHASE3 | Tozorakimab |
| GSK plc Sponsored ADR | GSK | 3 | PHASE1 | Pn-MAPS30plus, PCV20 |
| Pfizer Inc. | PFE | 4 | - | Undisclosed |
| Sanofi SA Sponsored ADR | SNY | 1 | - | Undisclosed |
| Gilead Sciences, Inc. | GILD | 1 | - | Undisclosed |
| Grace Therapeutics, Inc. | GRCE | 1 | N/A | Undisclosed |
Venticute is an investigational small molecule being developed for pneumonia. It is being studied in patients with pneumonia or aspiration of gastric contents who also have intubation, ventilation, or oxygenation impairment. The drug is currently in Phase 3 clinical development.
Venticute is being developed by Takeda Pharmaceutical Company Limited, which trades under the ticker TAK. The drug is currently in Phase 3 clinical development for the treatment of pneumonia.
Venticute is in Phase 3 clinical development. It is an investigational drug and has not been approved by regulatory authorities. One Phase 3 trial has been completed, involving 1,200 patients with pneumonia.
Venticute has one completed Phase 3 clinical trial, identified as NCT00074906. The trial studied Venticute in patients with pneumonia or aspiration of gastric contents and intubation, ventilation, or oxygenation impairment. It enrolled 1,200 participants across multiple countries.
Yes, the Phase 3 clinical trial of Venticute was randomized and double-blind. However, the trial was uncontrolled, meaning there was no comparator arm. The study enrolled 1,200 patients with pneumonia and related conditions.